Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00095628 · OUTCOME

Median Overall Survival of SB-715992

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · Source last updated 2017-03-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 18 months

What was measured

Overall survival is defined as the time from enrolment until death due to any cause. The Kaplan-Meier method was used to estimate overall survival.

Groups in this outcome

Treatment (Ispinesib)

Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ispinesib: Given IV laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ispinesib)20

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Ispinesib)3.5Not reported2.87.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.8
        upper Limit
        7.8
        value
        3.5
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Overall survival is defined as the time from enrolment until death due to any cause. The Kaplan-Meier method was used to estimate overall survival.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ispinesib: Given IV laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies
    id
    OG000
    title
    Treatment (Ispinesib)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 18 months
title
Median Overall Survival of SB-715992
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice